Filing Details
- Accession Number:
- 0001415889-22-001746
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-23 20:31:45
- Reporting Period:
- 2022-02-18
- Accepted Time:
- 2022-02-23 20:31:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1800 | Abbott Laboratories | ABT | Pharmaceutical Preparations (2834) | 360698440 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1867573 | L. Julie Tyler | 100 Abbott Park Road Abbott Park IL 60064 | Senior Vice President | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares Without Par Value | Acquisiton | 2022-02-18 | 10,482 | $0.00 | 36,254 | No | 4 | A | Direct | |
Common Shares Without Par Value | Disposition | 2022-02-19 | 281 | $116.79 | 35,973 | No | 4 | F | Direct | |
Common Shares Without Par Value | Disposition | 2022-02-21 | 342 | $116.79 | 35,631 | No | 4 | F | Direct | |
Common Shares Without Par Value | Disposition | 2022-02-22 | 466 | $116.79 | 35,165 | No | 4 | F | Direct | |
Common Shares Without Par Value | Disposition | 2022-02-22 | 462 | $119.29 | 34,703 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | F | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Option (right to buy) | Acquisiton | 2022-02-18 | 48,852 | $0.00 | 48,852 | $117.58 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
48,852 | 2023-02-18 | 2032-02-17 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Shares Without Par Value | 9,160 | Indirect | Profit Sharing Trust |
Footnotes
- These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.2904 to $119.302, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Balance in the Abbott Laboratories Stock Retirement Trust as of February 18 2022.
- Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024 and 16,284 on February 18, 2025.